why choose us

First received: September 06, 2022

Clinical Trial: UCD19 CAR T Therapy in Adults With B-ALL and MRD Positivity in CR1

Study Status: Completed

Recruit Status: RECRUITING

Condition: Acute Lymphoid Leukemia

Study Type: INTERVENTIONAL


Official Title: Phase I Safety and Tolerability Trial of CD19 Directed CAR T Cells in Adult Patients With B-Cell Acute Lymphoblastic Leukemia (B-ALL) With Minimal Residual Disease (MRD) Positivity at First Complete R

Brief Summary: This open-label, single arm Phase I trial aims to determine the safety and tolerability of anti-CD19 chimeric antigen receptor-expressing (CAR) T cells (UCD19 CAR T) in adults B-ALL that are in first complete remission with minimal residual disease (MRD) positivity.This trial will enroll 10 patients for apheresis and treatment with lymphodepleting chemotherapy followed by UCD19 CAR T cell infusion.Patients will be assessed for dose limiting toxicities (DLTs) (within 42 days after CAR T infusion), duration of B…

Read more